Video

Maximizing Stem Cell Transplantation in Multiple Myeloma

Related Videos
Jill Corre, PharmD, PhD
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Suzanne Lentzsch, MD, PhD
Rahul Banerjee, MD, FACP
Ajai Chari, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Related Content
Ashraf Z. Badros, MB, Ch
October 17th 2024

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
October 8th 2024

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Neha Korde, MD, of Memorial Sloan Kettering Cancer Center
October 2nd 2024

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma